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Eosinophilic fasciitis (Schulman’s syndrome) is a rare disease with speciﬁc clinical symptoms such as the groove sign which
facilitate diagnosis. We report a typical case of eosinophilic fasciitis in an otherwise healthy 49-year-old man who presented
with “prayer and groove signs”. Histological analysis showed sclerosis and eosinophilic inﬁltration of the fascia. The patient was
successfullytreated withsystemiccorticotherapy andCyclosporine.A shortreview ofthe clinicopathologicalfeatures ofthe lesions
is presented.
1.CaseReport
An otherwise healthy 49-year-old man presented with a
history of several months of severe fatigue with myalgia and
polyarthritis, rapidly worsening with painful swelling of legs
andhands, jointstiﬀness, and thickeningoftheskin. Hetook
neither medication nor toxic oil.
Physical examination revealed symmetrical lesions of
dermalsclerosiswith normalsuperﬁcial skin.Prayersigndue
to tenosynovitis of the hand (Figure 1), venous furrowing
(“groove sign” or “le signe du canyon” in France, Figure 2)
of the wrist, and arthritis in the feet and knees were
noted. We saw no telangiectasia, calcinosis, megacapillary,
sclerodactyly, or mucosal involvement. The patient showed
neither Raynaud phenomenon nor digital ulceration.
The capillary microscopy exam showed pericapillary
oedemaandcapillaryrarefaction correspondingtoanonspe-
ciﬁc microangiopathy.
Laboratory results showed hypereosinophilia (2063/
mm3) with an elevated C-reactive protein level (23mg/L),
transitory leucocytosis, and oligoclonal hypergammaglob-
ulinemia (IgG kappa and IgM lambda levels not measur-
able). Immunological results were normal or negative for
antinuclear antibodies, extractable nuclear antigens, antic-
itrullinated peptides, rheumatoid and complement factor.
Stoolswere normal, and the patient had received antiparasite
treatment (Ivermectine 1 day). The computed tomography
scan ofthe chest, abdomen,and pelvis was normal. Magnetic
resonance imaging (MRI) of the pelvis was normal at the
time of the initial symptoms and was not repeated.
A deep surgical biopsy of the left leg was performed. The
histological ﬁndings are shown in Figures 3 and 4.
The diagnosis of eosinophilic fasciitis (Schulman’s syn-
drome) was done.
2.Microscopic Findingsand ClinicalCourse
The surgical biopsy included skin, fascia, and muscle,
conﬁrmed the diagnosis ofeosinophilic fasciitis. Histological
analysis showed fascial sclerosis, lymphocytic, plasma cell,
and eosinophilic inﬁltration of the fascia, and muscle
and interlobular septae of panniculus. Thickening of the
interlobular septa of panniculus was seen without dermal
sclerosis (Figures 3 and 4).2 Pathology Research International
Figure 1: Prayer sign due to hand tenosynovitis.
Figure 2: Wrist with venous furrowing or the “groove sign”.
The patient received systemic corticotherapy, initially
1g of Solumedrol intravenous for two days then reduced
to 100mg per day for one week. Treatment was then
changed to oral Prednisone at 60mg with accompany-
ing immunosuppressive therapy (Cyclosporine 150mg/day).
Within one week, joint swelling, stiﬀness, oedema, and
laboratory abnormalities decreased. In conjunction with the
same level of Cyclosporine, the Prednisone was gradually
reduced to 30mg/day for one month, then to 10mg/day for
3 months. At 4 months, the patient completely recovered,
showing no symptoms. The oral Prednisone was reduced
to 3mg/day for the following 10 months and discontinued
thereafter. In the same time, Cyclosporine was reduced
to 50mg/day for 2 months, 25mg/day for 6 months,
then discontinued. At 12 months, all laboratory tests were
normal.
3.Discussion
Eosinophilic fasciitis was described in 1975 by Shulman [1]
andisregardedasavariantofscleroderma[2].Progressionto
scleroderma has been documented in several circumstances
[3]. Many conditions may appear similar such as hema-
tologic disease [4], Borrelia burgdorferi infection, toxicity
(oil, L-tryptophan) [5], and drug adverse event [6]. The
disease appears in 40- to 50-year-old men and women with
no sex bias, but it is seen earlier in men. Symmetrical and
distal, mainly forearm and leg, lesions classically appear after
trauma or physical eﬀort [7].
Figure 3: Histologic ﬁndings show thickening of the interlobular
septa of panniculus.
Figure 4: Fascial sclerosis with lymphocytic, plasma cell, and
eosinophilic inﬁltration.
The pathophysiology is unknown and unclear. Shakoory
et al. [8] suggest a role for mast cells and cytokines. Abnor-
mal circulating T-cell clones and increased interleukin-5
production could be responsible for the eosinophilia and
eosinophil-mediated tissue injury as suggested by French et
al. [9].
Dermatologic examination shows oedema, skin indura-
tion with a “peau d’orange” appearance, venous furrowing
(a very speciﬁc sign), and occasionally localised morphea.
Raynaud’s phenomenon is unusual. Capillary microscopy is
normal in 84% of cases, and systemic sclerosis is never seen
[10]. Joint and muscle pain, as well as asthenia, are frequent.
Joints contractions are linked to skin sclerosis, tenosynovitis
(carpal tunnel syndrome and prayer sign) with muscle, and
aponeurotic retraction.
Prayersigniscommon(56%)[11]butnonspeciﬁc.These
conditions can be seen in sclerodermiform diseases as well
as cheiroarthropathy, a limited joint mobility associated with
diabetes [12, 13].Pathology Research International 3
The main clinical diﬀerential diagnoses are sclerodermi-
form diseases including systemic sclerosis with Raynaud’s
phenomenon, calcinosis, megacapillary, a speciﬁc pattern in
capillary microscopy, and antinuclear antibodies, as well as
toxic oil syndrome and eosinophilia-myalgia syndrome due
to L-tryptophan intake [5]. These last 2 are clinically similar
to eosinophilic fasciitis; only anamnesis can distinguish
them.
Laboratory ﬁndings frequently show peripheral blood
eosinophilia, elevated sedimentation rates, and hypergam-
maglobulinemia (IgM or IgG). Hypereosinophilia is fre-
quently seen. The principal causes are dermatosis (atopic
dermatitis, urticaria, bullous pemphigoid, dermatitis her-
petiformis, and drug reaction), allergies, parasitic infection,
hematologic disease, cancer, or autoimmune diseases.
MRI is a very important diagnostic tool showing highly
characteristic signs: fascial thickening, hyperintense signal
within the fascia on ﬂuid-sensitive sequences, and fascial
enhancement after intravenous contrast administration.
MRIisusefulforguidedmusclebiopsy[14,15]which should
be performed to conﬁrm the diagnosis (deep skin biopsy,
ideally down to muscle).
Histology shows normal epidermis, rarely atrophic.
The dermis is often sclerotic with inﬂammatory inﬁltrate
composed of lymphocytes, eosinophils, plasma cells, and
histiocytes. Beneath the dermis, ﬁbrotic septae are seen
with the same inﬂammatory inﬁltrate, thick fascia with
sclerosis, and occasionally inﬂammatory polymorphic inﬁl-
trate with varying numbers of eosinophils. The eosinophilic
inﬁltrate can spread into the muscle ﬁbers. Histopathologic
diﬀerential diagnosis should rule out erythema nodosum,
bite reaction, parasite reaction, and Well’s syndrome. These
ﬁndings are similar and sometimes indistinguishable, par-
ticularly in superﬁcial biopsies and in cases where no
clinicalinformation isprovidedtothepathologist.Ifpresent,
eosinophilic inﬁltrate in fascia and muscle is speciﬁc, con-
trary to superﬁcial disorders. Thus a deep biopsy to include
muscle is ideal, preferably MRI guided.
Due to the rarity of this disease, it is diﬃcult to eval-
uate the eﬃcacy of eosinophilic fasciitis therapy. Frontline
treatment is corticosteroids [16], which often induce bio-
logical normalisation and total or partial clinical response.
Corticoid-sparingagentsaresometimes used[17–19],aswell
as immunosuppressive therapy (cyclosporine, cyclophos-
phamide, and azathioprine), hydroxychloroquine, dapsone,
or immunoglobulins eﬀectively, alone or combined. These
options, however, may be contraindicated by poor response
or adverse eﬀects.
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